9th Annual Biomarkers Congress

Drug Design: Health Canada

Total Score People Score Events Score
37 36 3
Date Event Presentation Speakers
November 3, 2010 DIA’s 8th Annual Canadian Meeting: “Keeping Canada on the Map: Fostering Innovation and Access to Drugs in Canada� Opening Plenary Session Kimby N. Barton
Establishment Licensing Renewal: Fostering a Safe Drug Supply Chain in Canada Merry J. Bujaki
TRACK 3 – Regulatory - Distributing Drugs in Today’s Global Environment: Regulatory Impact Daniela Decina
Canada: Your Location of Choice for Clinical Trials Brad Millson
The Personalized Medicine Landscape Clarissa Desjardins
Canada’s Perspective on Developing Regulatory Requirements for Products in Emerging Scientific Fields Elwyn Griffiths
TRACK 3 – Regulatory - International Collaboration: Use of Foreign Reviews in Canadian Regulatory Decisions, MRAs, and Confidentiality Agreements Alice Hui
Implementation of International Joint Review Karen Reynolds
TRACKS 2 and 3 – Reimbursement/Regulatory - Common Drug Review Pre-NOC Alice Hui
Adaptive Clinical Trials Designs: Issues and Considerations – A Regulatory Perspective Celia Lourenco
Personalized Medicine: Impact on Clinical Trial Design and Patient Recruitment? Brian Foster
Panel Discussion: “Ask the Regulators” Diana Dowthwaite, Elwyn Griffiths, Supriya Sharma, Nancy Richards
November 5, 2008 DIA's 6th Canadian Annual Meeting: Benefit and Risk Management: An Evolution in Progress THE EVOLVING LANDSCAPE OF BENEFIT AND RISK MANAGEMENT: HOW IS HEALTH CANADA ADAPTING? Marc Berthiaume
HEALTH CANADA’S HEALTH PRODUCTS AND FOOD BRANCH STRATEGIC PLAN Meena Ballantyne
PLANS TO ESTABLISH A PAN-CANADIAN DRUG SAFETY AND EFFECTIVENESS NETWORK Cynthia , Sunstrum
MARKETED HEALTH PRODUCTS DIRECTORATE’S (MHPD) CURRENT AND FUTURE ORIENTATIONS Chris , Turner
TRACK 1 : BEYOND SAFETY EVIDENCE IN THE POSTMARKETING ENVIRONMENT: THERAPEUTIC EFFECTIVENESS AT THE REGULATORY LEVEL Cindy Evans
TRACK 2 : CANADA VIGILANCE: IMPLEMENTATION OF A NEW PHARMACOVIGILANCE INFORMATION SYSTEM AT HEALTH CANADA Heather Sutcliffe
TRACK 2 : MEDDRA® IMPLEMENTATION WITHIN CANADA VIGILANCE AT HEALTH CANADA Michelle , Slow
TRACK 3 : HEALTH CANADA’S APPROACH TO REGULATING SEBS (SUBSEQUENT ENTRY BIOLOGICS) Kwasi , Nyarko
TRACK 2 : TOWARDS COMPREHENSIVE RISK MANAGEMENT PLANNING: HEALTH CANADA’S PROPOSED APPROACH Kimby N. Barton
TRACK 3 : VIGILANCE OF NATURAL HEALTH PRODUCTS Mano , Murty
TRACK 3 : ADULTERATION AND CONTAMINATION OF NATURAL HEALTH PRODUCTS: REGULATORY ISSUES AND CHALLENGES Harpal S. , Buttar
TRACK 2 : OPTIMISING BENEFITS AND MINIMISING RISKS OF DRUGS FOR PATIENTS: A PROPOSED WAY FORWARD Robyn Lim
TRACK 3 : THE REGULATOR’S PERSPECTIVE Ilhemme Djelouah
TRACK 1 : USE OF BIOMARKERS TO MEASURE THE PROGRESS OF DISEASE IN CLINICAL TRIALS AGNES V. , KLEIN
TRACK 2 : Speakers Guy Beaulieu, Brigitte Zirger
TRACK 3 : DRUG PRODUCT LIFECYCLE MANAGEMENT THROUGH PRODUCT DEVELOPMENT Krishnan , Tirunellai
TRACK 1 : Speakers Kimberly Empey, Mike D. Ward
TRACK 2 : EXPERIENCES WITH THE HYBRID ECTD: A REGULATORY PERSPECTIVE Claire-Marie Wray,
TRACK 2 : PLANS FOR SECURE ELECTRONIC TWO-WAY COMMUNICATION Douglas S. Watson
TRACK 2 : PLANS FOR ELECTRONIC CLINICAL TRIAL APPLICATIONS (CTA) REQUIREMENTS Martin Bernard
TRACK 3 : HEALTH CANADA’S NATURAL HEALTH PRODUCTS PROGRAM: BLACK COHOSH AS A CASE STUDY OF WORKING TOGETHER TO INCREASE PRODUCT SAFETY Scott A. , Jordan
TRACK 3 : MONITORING NHP ADVERSE REACTIONS: A SHARED RESPONSIBILITY BETWEEN THE REGULATOR, CONSUMER, HEALTH PROFESSIONAL, AND THE INDUSTRY Scott A. , Jordan
October 16, 2007 Second Annual Putting Theory into Practice: Adaptive Clinical Trial Designs (Oct 16-17 SESSION II: REGULATORY PERSPECTIVES AND LESSONS LEARNED FROM CONDUCTING STUDIES WITH ADAPTIVE TRIAL DESIGNS (08:30-11:15) Dietlind Gardell
SESSION II: Regulatory Perspectives in Adaptive Trial Design (08:45-09:15) Dietlind Gardell
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.